Results 101 to 110 of about 681,456 (227)

The Longer‐Term Impact of Biosimilar Switching Policies in Patients With Inflammatory Bowel Disease in British Columbia, Canada: A Retrospective, Population‐Based Study

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Background and Aims In 2019, British Columbia (BC) became the first jurisdiction in North America to introduce a mandatory non‐medical switching (NMS) policy requiring patients with Crohn's disease (CD) and ulcerative colitis (UC) to be switched from originator biologics to biosimilar equivalents.
Mark Harrison, Sandra Blitz, Michael Law, Mina Tadrous, Tara Gomes, Fiona Clement, Greg Rosenfeld, Aslam Anis, Nick Bansback   +8 more
wiley   +1 more source

Review on lipegfilgrastim

International Journal of Nanomedicine, 2015
Maja Gasparic, Sophie LeymanTeva Pharmaceuticals Europe BV, European Headquarters, Amsterdam, the NetherlandsHaving read the original Hoggatt et al article1 and the corrigendum published online on August 27, 2015,2 we do not consider the description of ...
Gasparic M, Leyman S
doaj  

European Network on Optimizing Treatment With Therapeutic Antibodies in Chronic Inflammatory Diseases: Overview, Progress and Perspectives

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Treatment of chronic inflammatory diseases has been revolutionized with the introduction of targeted therapies using therapeutic antibodies. However, a large proportion of patients do not respond to treatment, or they lose response over time.
Konstantin Tachkov, Merita Rumano, James Bluett, Nataša Bogavac‐Stanojević, Erwin Dreesen, Mehmet Itik, Georgios Kararigas, Paweł Kawalec, Marlene Santos, Silje Skrede, Guenka Petrova, Denis Mulleman   +11 more
wiley   +1 more source

Evolution of Biosimilar Medicines on the Romanian Pharmaceutical Market

Acta Pharmaceutica Hungarica, 2021
Emese Sipos, Emőke Rédai, Ibolya Fülöp   +2 more
openaire   +1 more source

Net Present Value Impact of FDA’s Phase 3 Waivers on Monoclonal Antibody Biosimilar Development

Biologics: Targets & Therapy
Ranjit Ranbhor,1 Priyanka Kulkarni2 1Business Development, Portfolio and Patents, Odin Pharmaceuticals LLC, Somerset, NJ, USA; 2Feliciano School of Business, Montclair State University, Montclair, NJ, USACorrespondence: Ranjit Ranbhor, Business ...
Ranbhor R, Kulkarni P
doaj  

The introduction of biosimilars of low molecular weight heparins in Europe: a critical review and reappraisal endorsed by the Italian Society for Haemostasis and Thrombosis (SISET) and the Italian Society for Angiology and Vascular Medicine (SIAPAV)

Thrombosis Journal, 2017
Recently, the European Medicines Agency (EMA) authorized the introduction and marketing of Thorinane® and Inhixa®, biosimilars of the Low Molecular Weight Heparin (LMWH) enoxaparin.
Davide Imberti, Marco Marietta, Hernan Polo Friz, Claudio Cimminiello   +3 more
doaj   +1 more source

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar

ClinicoEconomics and Outcomes Research, 2018
Lee S Schwartzberg,1,2 Lincy S Lal,3 Sanjeev Balu,4 Kim Campbell,4 Lee Brekke,3 Caitlin Elliott,3 Stephanie Korrer3 1West Cancer Center, Memphis, TN, USA; 2Division of Hematology and Oncology, University of Tennessee, Memphis, TN, USA; 3Health Economics ...
Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, Elliott C, Korrer S   +6 more
doaj  

A PHARMACEUTICAL GUIDE TO ADALIMUMAB BIOSIMILARS

FARMACIA, 2022
openaire   +1 more source

Impact of biosimilar medicinal products in the EU pharmaceutical market [PDF]

Clinical Therapeutics, 2015
A. Grozdanova, K. Ancevska Netkovska, Z. Sterjev, Z. Naumovska, A. Kapedanovska Nestorovska, L.j Suturkova   +5 more
openaire   +1 more source

REGULATORY AND ANALYTICAL SCIENCE OF BIOSIMILARS: A PHARMACEUTICAL CHEMISTRY PERSPECTIVE

The development and approval of biosimilars represent a significant advancement in pharmaceutical science, offering cost-effective therapeutic alternatives to originator biologics. From a pharmaceutical chemistry perspective, the regulatory and analytical evaluation of biosimilars demands a rigorous, multidisciplinary approach to ensure comparable ...
openaire   +2 more sources